Logo

Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics

Share this

Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics

Shots:

  • Nosopharm and Evotec collaborated to advance Nosopharm’s NOSO-502 to clinical stage and to develop second-generation Odilorhabdin (ODLs) for hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP)- under the name NOSO-2G
  • The collaboration initially focuses on Chemistry- Manufacturing and Control (CMC) and Clinical Trial Application (CTA)-enabling and filing activities regarding NOSO-502 for the onset of P-I study of NOSO-502 for the treatment of cUTI & cIAI
  • NOSO-502 belongs to the class of ODLs inhibiting bacterial ribosomes and is intended to treat nosocomial infections by Enterobacteriaceae with its expected CTA-filing and initiation of clinical study in 2021

Click here to read full press release/ article | Ref: Nosopharm | Image: Evotec


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions